EXELON PATCH 5 (4.6MG/24HR)

Product Information

Registration Status: Active

EXELON PATCH 5 (4.6MG/24HR) is approved to be sold in Singapore with effective from 2008-04-28. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN13450P.

This product contains Rivastigmine 9mg/5cm2 in the form of PATCH, EXTENDED-RELEASE. It is approved for TRANSDERMAL use.

This product is manufactured by LTS Lohmann Therapie-Systeme AG in GERMANY.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Rivastigmine

Description

Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication

For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Mechanism of Action

Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

Clearance

* renal cl=2.1-2.8 L/hr

Active Ingredient/Synonyms

(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate | m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate | Rivastigmine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank